Objective: To test the hypothesis that polycystic ovary syndrome (PCOS) is associated with an increased risk of atherosclerotic cardiovascular disease (CVD) in older postmenopausal women.
P olycystic ovary syndrome (PCOS) is held to be the most prevalent endocrine disorder among women of reproductive age. 1<4 The syndrome commonly presents in adolescence or early adulthood as hyperandrogenism, often in concert with chronic anovulation and infertility. 5<7 Cardiovascular disease (CVD) risk in women with PCOS may be enhanced through associations with insulin resistance, diabetes mellitus, and other components of the metabolic syndrome. 8<11 Clinical practice guidelines stress the importance of identifying modifiable CVD risk factors in younger women with PCOS. 8, 9 However, few data are available concerning the health implications of PCOS for older women. 12 Among premenopausal women with PCOS, high prevalence rates of dyslipidemia, central obesity, and diabetes 13<15 and evidence of accelerated subclinical atheroma 13, 16 provide a priori evidence of an increased risk of atherosclerosis. 17, 18 To date, however, no clear evidence of an excess of CVD or death has emerged from epidemiologic studies. 16, 19, 20 The reasons for this discrepancy have been extensively debated. Some studies included women who had undergone ovarian surgical intervention that might have obscured any association. No studies to date have tested the hypothesis that CVD may become apparent only after menopause, when atherosclerosis is most prevalent. 16, 21 In this study we identified individuals with a putative PCOS phenotype from among a cohort of community-dwelling postmenopausal women. Women taking hormone therapy were excluded. A review of the literature prompted us to stratify our analysis to exclude the potential confounding factors of diabetes and previous oophorectomy.
METHODS

Study cohort
Between 1984 and 1987, 82% of the surviving women from the Rancho Bernardo Study, a middleclass white cohort resident in southern California, participated in a clinical study focusing on diabetes. From this cohort we identified 713 women older than 50 years who were not taking hormone therapy. All the women were at least 1 year beyond their last menstrual period, and all had plasma estradiol concentrations less than 100 pmol/L. Height, weight, waist girth, and hip girth were measured in participants, who wore lightweight clothing without shoes. Body mass index was calculated as weight (kg)/ height (m 2 ). Diabetes was diagnosed on the basis of medical history or hyperglycemia, according to American Diabetes Association criteria (ie, fasting plasma glucose Q7.0 and/or 2-h glucose Q11.1 mmol/L after a 75-g oral glucose challenge 22 ). A history of unilateral or bilateral oophorectomy was sought from all women. Medical records were obtained for 228 of 614 women who reported a history of hysterectomy; 96.5% of the women reporting bilateral oophorectomy and 67.5% of women reporting ovarian conservation had confirmatory medical records. 23 
Laboratory methods
Fasting venous blood samples were obtained, and plasma was frozen at j70-C. Sex steroid hormones were measured on first-thawed samples between 1992 and 1993 in the Department of Reproductive Medicine Research Laboratory, University of California San Diego, using radioimmunoassay after solvent extraction and celite column chromatography. Steroids are stable for at least 10 years in frozen plasma. 24 Sex hormoneY binding globulin (SHBG) was determined by the method of Rosner, 25 and bioavailable testosterone and estradiol (the non-SHBG-bound fractions) were measured using a method modified from Tremblay and Dube. 26 The sensitivity and intra-and interassay coefficients of variation have been reported elsewhere. 27 Plasma glucose was measured using a glucose oxidase assay. Fasting plasma insulin was determined in a substudy of 390 women using a double-antibody radioimmunoassay. 28 Insulin resistance was assessed using the homeostasis model assessment for insulin resistance (HOMAVIR) according to the following formula 29,30 : fasting glucose ðmmol=LÞÂ fasting insulin ðmU=LÞ Ä 22:5:
Cholesterol and triglycerides were measured by enzymatic methods with an ABA-200 biochromatic analyzer (Abbott, Irving, TX). High-density lipoprotein cholesterol was measured by precipitation according to the Lipid Research Clinics Program protocol 31 ; low-density lipoprotein cholesterol was calculated using the formula of Friedewald and colleagues. 32 High-sensitivity C-reactive protein was measured by immunoassay (Dade Behring, Inc., Deerfield, IL) with a coefficient of variation of 7.7%. 33 
Ascertainment of prevalent CVD and coronary heart disease
The presence of coronary heart disease (CHD) was defined by any of the following: Rose questionnaire severe angina score, 34 history of heart disease diagnosed by a physician (validated for 85% of the 30% subset whose hospital records were requested), history of coronary revascularization, or major electrocardiographic abnormalities. A 12-lead resting electrocardiogram was performed and coded at the University of Minnesota. 35 Myocardial infarction was defined by the presence of major electrocardiographic Q-wave abnormalities (Minnesota codes 1.1 and 1.2), a history of physician-diagnosed heart attack, or severe chest pain lasting for more than 30 minutes. Cerebrovascular disease was defined as a history of stroke, transient cerebral ischemic attack, or carotid-intracerebral arterial surgery. Lower extremity arterial disease was identified by claudication using the Rose questionnaire. 34 CVD was defined as the sum of CHD, cerebrovascular disease, and lower extremity arterial disease.
Definition of the PCOS phenotype
Clinical and biochemical criteria were selected to identify women with features of PCOS in accordance with the literature. 8, 9, 36 Because these features cluster together in variable associations in individuals, we defined our phenotype as the presence of three or more of the following: (1) a history of irregular menses, defined as being too irregular to recall between the ages of 20 and 40 years; (2) hirsutism, defined as excessive facial hair on the chin and/or upper lip or androgenic pattern hair loss (ie, receding hair line or loss of hair over vertex) before the age of 50 years as reported in a structured, self-administered questionnaire or current biochemical evidence of relative hyperandrogenism (ie, values in the highest quintile for total testosterone or bioavailable testosterone or the lowest quintile for SHBG); (3) a history of personal infertility (ie, unable to conceive for reasons not attributable to partner or inability to carry pregnancies to term 37 ); (4) central obesity, defined as a waist circumference greater than 88 cm 38 ; or (5) insulin resistance, defined either as a HOMA-IR value in the top quintile for the cohort 29 or, in women (n = 216) for whom insulin levels were not available, a fasting plasma glucose concentration Q6.1 mmol/L (a proxy marker of insulin resistance as suggested by the 2001 report of the National Cholesterol Education Program 38 ).
Statistical analysis
Data were analyzed using SPSS for Windows, version 11.5 (SPSS Inc, Chicago, IL). Immunoreactive insulin, HOMA-IR, and sex steroid hormones did not follow a normal distribution. However, because results did not differ between analyses based on untransformed and log-transformed variables, untransformed data are presented. For quintile analysis, the highest or lowest quintile, depending on the variable, was compared with the remaining four quintiles. Unadjusted associations between potential predictors and cardiovascular disease were evaluated using Student`s t test and W 2 tests as appropriate. One-way analysis of variance was used to examine differences between the means of more than two groups, followed by post hoc tests where appropriate. Binary logistic regression was used to examine the effect of covariates on the association between PCOS and prevalent CVD. Because some of the variables that defined the PCOS phenotype are closely associated with diabetes, itself a powerful risk factor for CVD, the analysis was stratified by diabetes status. Data were analyzed before and after exclusion of women with a history of unilateral or bilateral oophorectomy. All P values are two tailed. Statistical significance was defined as P G 0.05.
Ethics approval
Written informed consent was obtained from all women. The study was approved by the institutional review board of University of California San Diego.
RESULTS
Clinical and biochemical characteristics of the cohort
The mean (T SD) age of the 713 women was 74 T 8 years (range, 51<89); mean body mass index was 24.0 T 3.5 kg/m 2 . Diabetes mellitus was present in 107 women (15% of total). Among the women with diabetes, 29 were already known to have the disorder, and the remainder were new cases identified by glucose tolerance tests. Of the women with known diabetes, 16 were being treated with antidiabetic agents at the time of the study. Among the 601 nondiabetic women, 310 (43.5%) had normal glucose tolerance; the remaining women had either impaired glucose tolerance (n = 195, 27.3%) or impaired fasting plasma glucose as defined by American Diabetes Association criteria 22 ; glucose tolerance status was unclassifiable in five women (0.7%). A history of single (n = 47) or bilateral (n = 120) oophorectomy was reported by 167 (23.4%) women. Total testosterone concentration was significantly lower in women with a history of either single or bilateral (P G 0.05 for each) oophorectomy compared with intact women (0.35 T 0.24 vs 0.54 + 0.47 vs 0.65 T 0.46 nmol/L, respectively; F = 24.9, P G 0.01 between the groups).
Association of PCOS phenotype with cardiovascular risk factors
The prevalence of the putative PCOS phenotype (ie, three or more criteria as defined above) among the entire cohort was 9.3%; among nondiabetic women the prevalence of the phenotype was lower at 5.8%. Clinical and biochemical data for the PCOS versus unaffected women are presented in Table 1 . As expected from the selection criteria, statistically significant differences were observed between those with versus those without PCOS for waist circumference, bioavailable testosterone, SHBG, and HOMA-IR. Plasma total and bioavailable estradiol concentrations were significantly higher in women with the PCOS phenotype compared with unaffected women (P G 0.01; Table 1 ). The proportion of women reporting a history of cigarette smoking or estrogen-progestogen use, current physical activity or exercise three or more times weekly, and single or bilateral oophorectomy did not differ according to the presence or absence of the PCOS phenotype (Table 1) .
The percentages of affected and unaffected women with each of the main features of the PCOS phenotype are presented in Table 2 . Among women with the PCOS phenotype, the frequency of relevant symptoms did not differ by diabetes status (Fig. 1 ). However, high waist circumference, hyperandrogenism, and insulin resistance were more common in diabetic women with the PCOS phenotype than in nondiabetic women with the phenotype (P G 0.01 for each; Fig. 1 ).
Relationship of the PCOS phenotype to prevalent CVD
The prevalence of CVD was similar between women with PCOS status and unaffected women (27.3% vs 24.4%). When the analysis was confined to nondiabetic women with intact ovaries, a significant age-adjusted, stepwise graded association was observed between an increasing number of features of the PCOS phenotype (ie, none to three or more) and prevalent CVD (P = 0.02; Table 3 ). This association was also evident for CHD alone (P = 0.03; Table 3 ).
DISCUSSION
Our objective was to identify major clinical and biochemical features of PCOS among a well-characterized cohort of non-hormone-using postmenopausal women and examine the PCOS association with CVD. For nondiabetic women with intact ovaries, we observed a stepwise graded association between key features of our putative PCOS phenotype and prevalent CVD. We believe that our study is the first to describe PCOS and CVD in exclusively postmenopausal women and to provide support for the thesis that PCOS increases the risk of CVD in later life. In addition, prevalent CVD increases as a function of the number of features of the syndrome.
Several retrospective studies have suggested an increased risk of atherosclerotic CVD in women with PCOS. 39, 40 In case-control studies, the severity of surrogate markers of atherosclerosis in premenopausal women, including coronary calcification scores, 17,41 carotid intima-media thickness, and adverse electrocardiographic features 42 was increased in women with PCOS as compared with controls. 43 However, a higher prevalence of undiagnosed glucose intolerance and/or diabetes in women with PCOS 9 might partially explain these findings. 44 In a small single-center study of women with a mean age of approximately 60 years undergoing coronary angiography, hirsutism was more commonly reported by women with stenotic coronary disease. 39 However, assessment of coronary disease by angiography is now recognized to be a relatively poor indicator of the true extent of coronary atherosclerosis. 45 Prospective studies have produced equivocal results. In a UK study of 786 women with PCOS diagnosed on the basis of macroscopic or histologic criteria, Pierpoint et al 46 found no increased risk of CVD compared with national rates. Additional follow-up of this cohort in middle age 15 found no excess of CHD morbidity or mortality, but increased rates of self-reported cerebrovascular disease and diabetes were observed. Of note, a high proportion (75%) of the women in this cohort had a history of surgical ovarian wedge resection. 46 We hypothesized that high rates of ovarian surgery in Western countries may confound epidemiologic studies of the association between PCOS and CVD. The high rates of oophorectomy in the United States provide support for this contention: more than 25% of women have had a hysterectomy before age 60 47 ; this procedure is often accompanied by elective oophorectomy. 48 Even wedge resection of the ovaries can reportedly improve menstrual patterns for decades. 49 However, it is not known whether cardiovascular risk is modified by hysterectomy or oophorectomy. 50, 51 Levels of endogenous androgens may be pertinent to this issue, 52 although testosterone is generally thought to contribute little to the insulin resistance of PCOS. It has been reported that relative hyperandrogenism may persist into the postmenopausal years among women with PCOS who have intact ovaries. 53 The association between endogenous androgens and cardiovascular risk remains uncertain, 54 and it is unclear whether reduced testosterone levels after oophorectomy alter the link between PCOS and CVD. 20 In a previous report from the Rancho Bernardo Study, testosterone levels were approximately 40% lower in postmenopausal women who had a history of hysterectomy and bilateral oophorectomy compared to intact women. 55 In the present study testosterone levels were significantly lower in women with unilateral or bilateral oophorectomy, with a doseeffect association. 
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There is a clear need for further studies. Diagnosing PCOS retrospectively in oophorectomized women is clearly fraught with theoretical and practical difficulties. Other steroid hormones may be relevant to CVD risk. Adrenal androgen production is reportedly increased in some women with PCOS. 56 It has been suggested that higher levels of dehydroepiandrosterone sulfate might protect women with PCOS against atherosclerosis. 57 We found no increase in dehydroepiandrosterone sulfate levels in women with the PCOS phenotype as we defined it. Total and bioavailable estradiol levels were significantly higher in the women with the PCOS phenotype, a difference that possibly reflects the presence of greater adiposity or diabetes. 58 Among premenopausal women, the absence of universally agreed-on diagnostic criteria for PCOS and the paucity of long-term follow-up studies have contributed to the uncertainty about the long-term risk of CVD. 16, 59, 60 Although the diagnosis of PCOS may be more reliable in premenopausal than postmenopausal women, the absolute CVD risk in this age group is intrinsically low. 4 The risk of CVD is higher after menopause, yet the diagnosis of PCOS in postmenopausal women presents investigators with additional challenges. Using current knowledge, we aimed to identify a phenotype that incorporated the major clinicopathologic features associated with PCOS, particularly those likely to be associated with CVD risk.
Recent studies have suggested that self-reported symptoms of oligomenorrhea and hirsutism can identify women at elevated risk of CVD. 61 Longitudinal cohort studies have shown that a history of irregular menses predicts the development of both CVD 62 and diabetes. 63 A recent cross-sectional study from Finland reported that premenopausal women with oligomenorrhea and/or hirsutism were more likely to have adverse cardiovascular risk profiles than asymptomatic women. 64 A recent US study found that menstrual irregularity identified mothers of women with PCOS who also have features of the syndrome. 12 An association between irregular periods and insulin resistance has been reported, 65 which suggests a potential mechanism by which menstrual irregularity might affect CVD risk. Accordingly, we found an unfavorable plasma lipid profile among the women with the putative PCOS phenotype 16, 19 : fasting triglycerides were elevated, but mean highdensity lipoprotein cholesterol concentrations were reduced; these changes were independent of diabetes status. Other studies have shown that reduced high-density lipoprotein cholesterol levels are associated with obesity, insulin resistance, 66 and low concentrations of SHBG in women with PCOS. 67 It is well recognized that central adiposity may be present even in the absence of generalized obesity in women with PCOS. 68, 69 We used a waist girth of more than 88 cm as a proxy measure of abdominal obesity, as recommended by the 2001 National Cholesterol Education Program Adult Treatment Panel 38 and subsequently adopted by the 2003 Rotterdam Consensus Conference on PCOS. 8 Abdominal obesity is associated with activation of the innate immune system, a defect implicated in atherogenesis. 70, 71 However, we found no increase in Creactive protein levels in women with the PCOS phenotype compared to unaffected women (data not shown).
The prevalence of the PCOS phenotype in our study was 5.8% among nondiabetic women. This figure is very similar to prevalence rates reported in the literature, 1, 2, 4 although women in the Rancho Bernardo Study are almost exclusively white and leaner than a representative sample of white US women. 72 Azziz and colleagues 3 reported a cumulative prevalence of 6.6% in a mixed-race sample of US women, whereas Diamanti-Kandarakis and colleagues 73 and Asuncion and colleagues 74 found prevalence rates of 6.8% and 6.5% among premenopausal Greek and Spanish women, respectively.
Previous studies that examined the association between PCOS and CVD have not always rigorously excluded women with undiagnosed diabetes. This is important because several components of the PCOS phenotype, ie, menstrual irregularity, 63 hyperandrogenism, 5,58 central obesity, 75 and insulin resistance, 9, 76 are associated with diabetes. The prevalence of PCOS in our cohort increased to 9.3% when women with diabetes were included. 4, 5 The majority of women with diabetes in our study were identified using oral glucose tolerance tests, currently the most sensitive diagnostic method. 22 We acknowledge several limitations of our study. First, ovarian imaging and a medical record of physician-confirmed PCOS were not available. However, appearance on pelvic ultrasonography does not necessarily correlate well with clinical and biochemical features, and ovarian imaging is not required to make a diagnosis of PCOS. 8, 77 In fact, as many as 25% of apparently healthy women with regular menstrual cycles have polycystic ovary morphology 9 accompanied by degrees of insulin resistance. 78 Second, the reported premenopausal clinical history (hirsutism, oligomenorrhea) may not have been correctly recalled by older women. Although we were unable to exclude alternative causes of oligomenorrhea or hyperandrogenism, clinical practice suggests that these are likely to have been uncommon among community-dwelling women. 79 Similarly, reported infertility or inability to take a pregnancy to term may have had causes other than PCOS. Third, we included clinical and subclinical CVD in our analysis when it is acknowledged that the diagnosis of CHD can be problematic in women. 80 To reduce the nonspecificity of chest pain in women, we included only those individuals with severe angina scores on the Rose questionnaire. 34 We used HOMA-IR in place of the gold standard euglycemic hyperinsulinemic clamp technique 81 to measure insulin resistance. 82 HOMA-IR seems to be a valid marker of insulin resistance and is generally regarded as a practical alternative to the clamp technique in epidemiologic studies. 83 However, there are some reservations about the reliability of HOMA-IR in the presence of hyperglycemia. The cross-sectional design of our study cannot exclude selective cardiovascular mortality in more severely affected women. Such a survivor effect would reduce the ability to identify an association between PCOS and CVD.
Perhaps the most challenging issue is that of defining a PCOS phenotype in older women. Because no gold-standard diagnostic criteria exist, of necessity we have had to base our definition on current views of the pathophysiology of PCOS. Because there is overlap between PCOS and the broader metabolic syndrome of cardiovascular risk, 9, 11 our study should be regarded as an exploratory attempt to identify PCOS in postmenopausal women. Strengths of our study include the well-characterized cohort, exclusion of women taking hormone therapy, accurate ascertainment of diabetes status, and the validated history of oophorectomy.
CONCLUSIONS
In summary, we found a stepwise graded association between components of a PCOS phenotype and prevalent atherosclerotic CVD in a cohort of nonestrogen-using postmenopausal women. This association was evident in only nondiabetic women and was obscured by a history of oophorectomy. The latter observation suggests that oophorectomy may be a confounding factor in studies of the association between PCOS and CVD. In conclusion, we believe that our findings provide support for the thesis that PCOS increases the risk of CVD in postmenopausal women.
